A research-focused healthcare company, Roche discovers, develops and provides innovative diagnostic and therapeutic products and services that deliver significant benefits to patients and healthcare professionals – from early detection and prevention of diseases to diagnosis, treatment, and treatment monitoring.


Roche was founded on October 1st, 1896. The founder, Fritz Hoffmann-La Roche, was among the first to recognize that the industrial manufacture of standardized medicines would be a major advance in the fight against disease.


From the very beginning, Roche’s visionary founder focused his company on innovation and on establishing an international presence. This multinational presence reinforces our ability to offer our healthcare solutions and to anticipate needs in all regions of the world. Today, Roche employs over 80,000 people and sells its products in over 150 countries.


Today Roche ranks among the world’s leading healthcare companies and has two strong core businesses: diagnostics and pharmaceuticals.


Roche’s prime objective is to identify and meet the patient’s and customers’ needs. This implies solving their problems and anticipating their future needs by maintaining close contact with them and listening to what they say.


At Roche we focus our resources on two research intensive businesses: pharmaceuticals and diagnostics. Within these businesses we prioritize those areas of significant unmet need where we have the expertise to make a difference. Our aim is to develop new and improved drugs, diagnostic tests and services offering significant benefits over existing options.


By innovation we mean the creation and commercialization of medically differentiated products and services that lead to a tangible improvement to the health, quality and length of patients’ lives.


As a research-focused company we exploit the latest discoveries and technologies to develop our products.

This is why

  • Roche invested over 8 billion Swiss francs in 2011 on research and development.
  • Roche continues its longstanding tradition of working in alliances with some of the most forward-looking and technologically advanced companies in the world.
  • Roche invests heavily in biotechnology and is the world’s largest biotechnology company.


Cooperation and social dialogue with external partners and stakeholder groups is important to Roche. Topics such as research and development of pharmaceuticals, innovation in the healthcare field, or access to medical care are high-priority issues and while pharmaceutical companies are only one part of the solution, we believe we have a duty to society and to our stakeholders to make balanced, constructive contributions to the public debate on these wide range of issues. In order to do this, we work closely with the relevant government offices, regulatory authorities and non-government organizations both globally and at the local level, to help shape opinion on proposed legal or political changes by making informed contributions to the public debate on such changes. At the local level it is particularly important to work with governmental organizations. If legal or political changes are planned, we want to be able to have our say and take care that the conditions affecting our ability to perform competitively are not restricted. We are also able to contribute to the improvement of relations between society and the whole healthcare sector.


Cooperation with many national and international organizations, government offices and non-governmental organizations takes place at every level: activities are coordinated and supported at the corporate level by Corporate Public Affairs and the Chairman’s Office, at the divisional level by divisional regulatory and public affairs specialists. These act in the same way as local affiliates who respond in accordance with legal requirements, tradition and the given situation. All Roche affiliates, management and concerned Roche employees can have access to Roche’s positioning on important questions, which are also documented on the web.


Our commitment focuses on working with the following organisations. Roche is actively represented in most of these organisations by senior members of management:

  • European Roundtable of Industrialists (ERT)
  • economiesuisse
  • SwissHoldings
  • Swiss Society of Chemical Industries (SSCI)
  • European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • Pharmaceutical Research and Manufacturers of America (PhRMA)
  • International Federation of Pharmaceutical Manufacturers Associations (IFPMA)
  • Emerging Biopharmaceutical Enterprises (EBE)
  • Biotechnology Industry Association of America (BIO)
  • Interpharma
  • Advanced Medical Technology Association (AdvaMed)
  • European Diagnostic Manufacturers Association (EDMA)
  • Japanese Pharmaceutical Manufacturers Association (JPMA)

Roche’s involvement occurs within a context of openness and transparency:

  • Unless specifically stated otherwise, Roche supports jointly developed platforms and positions and is committed to them.
  • Roche limits its involvement to selected organisations and areas that are directly related to its corporate mission or the basic conditions required to fulfil that mission.
  • Roche joins an organisation only if active involvement within the organisation, either in a leadership role or in working groups, is possible and desirable. The commitment must be specific and long-term, if feasible.
  • We have a right and a duty to contribute to the debate on public policy issues by bringing relevant facts and consequences to the attention of government policy makers, but we will never interfere with their decision-making authority.
  • It is Roche policy not to take a public position on an matter involving party politics or religion.


Roche is of the opinion that any dialogue and engagement with Government Officials need to be conducted in a proactive, honest, transparent, responsible and sustainable manner. For this reason we have developed Good Practice Guidelines “Guidelines” [ link to Guidelines] that set forth the principles which should determine any relationship between Roche and Government officials. By implementing these Guidelines, Roche intends to maintain the highest professional standards and act as a trustworthy and legitimate partners for Government officials. In addition, Roche expects and requests that any contractor or agency working for Roche or on behalf of Roche, including for example public affairs agencies, public relations agencies and lobbyists, must also fully abide by the provisions in the Guidelines when engaging with Government officials for or on behalf of Roche.


Roche has developed its own policy on safety, security, health and environmental protection (SHE) and regularly produces positions papers on such topics as:

  • Biodiversity- Safety, Health and Environmental Aspects
  • Greenhouse Gases & Climate Change
  • Landfills
  • Water
  • Energy
  • Biodiversity
  • Prevention of misuse of biological material and toxins for bio warfare
  • Pharmaceuticals in the environment
  • Pollution, prevention and reduction
  • Product Stewardship
  • Waste Management

as well as Fact Sheets (e.g. hybrid cars, ECOmpetition, climate change)